Does the media favor DNTH or MRNA?

In the previous week, Moderna had 99 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 113 mentions for Moderna and 14 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat Moderna's score of 0.38 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 46 Very Positive mention(s) 16 Positive mention(s) 14 Neutral mention(s) 18 Negative mention(s) 14 Very Negative mention(s) Neutral

Does the media prefer DNTH or BNTX?

In the previous week, BioNTech had 6 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 20 mentions for BioNTech and 14 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat BioNTech's score of 0.09 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 5 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media prefer DNTH or UTHR?

In the previous week, United Therapeutics had 21 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 35 mentions for United Therapeutics and 14 mentions for Dianthus Therapeutics. United Therapeutics' average media sentiment score of 1.13 beat Dianthus Therapeutics' score of 1.01 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 26 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GMAB or DNTH?

In the previous week, Dianthus Therapeutics had 13 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Dianthus Therapeutics and 1 mentions for Genmab A/S. Dianthus Therapeutics' average media sentiment score of 1.01 beat Genmab A/S's score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNTH or BBIO?

In the previous week, Dianthus Therapeutics had 8 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Dianthus Therapeutics and 6 mentions for BridgeBio Pharma. Dianthus Therapeutics' average media sentiment score of 1.01 beat BridgeBio Pharma's score of 0.29 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Dianthus Therapeutics (DNTH) Competitors

$111.10 +1.59 (+1.45%)

As of 08/21/2026 04:00 PM Eastern

Compare

DNTH vs. MRNA, BNTX, UTHR, GMAB, and BBIO

Should you buy Dianthus Therapeutics stock or one of its competitors? Dianthus Therapeutics's main competitors and comparable companies include Moderna (MRNA), BioNTech (BNTX), United Therapeutics (UTHR), Genmab A/S (GMAB), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dianthus Therapeutics compare to Moderna?

Dianthus Therapeutics (NASDAQ:DNTH) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Moderna has a net margin of -141.43% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Moderna	-141.43%	-28.30%	-19.39%

Dianthus Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Dianthus Therapeutics has higher earnings, but lower revenue than Moderna. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,977.37	-$162.34M	-$4.15	N/A
Moderna	$1.94B	29.79	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 99 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 113 mentions for Moderna and 14 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat Moderna's score of 0.38 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	46 Very Positive mention(s)	16 Positive mention(s)	14 Neutral mention(s)	18 Negative mention(s)	14 Very Negative mention(s)	Neutral

Dianthus Therapeutics presently has a consensus price target of $124.27, indicating a potential upside of 11.86%. Moderna has a consensus price target of $69.50, indicating a potential downside of 52.09%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Dianthus Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Dianthus Therapeutics beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to BioNTech?

Dianthus Therapeutics (NASDAQ:DNTH) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Dianthus Therapeutics presently has a consensus price target of $124.27, suggesting a potential upside of 11.86%. BioNTech has a consensus price target of $127.81, suggesting a potential upside of 9.64%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dianthus Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

In the previous week, BioNTech had 6 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 20 mentions for BioNTech and 14 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat BioNTech's score of 0.09 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	5 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Neutral

Dianthus Therapeutics has higher earnings, but lower revenue than BioNTech. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,977.37	-$162.34M	-$4.15	N/A
BioNTech	$3.25B	9.08	-$1.29B	-$7.83	N/A

BioNTech has a net margin of -63.54% compared to Dianthus Therapeutics' net margin of -10,096.95%. BioNTech's return on equity of -6.86% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
BioNTech	-63.54%	-6.86%	-6.00%

Summary

BioNTech beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to United Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, United Therapeutics had 21 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 35 mentions for United Therapeutics and 14 mentions for Dianthus Therapeutics. United Therapeutics' average media sentiment score of 1.13 beat Dianthus Therapeutics' score of 1.01 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	26 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics currently has a consensus target price of $124.27, suggesting a potential upside of 11.86%. United Therapeutics has a consensus target price of $646.00, suggesting a potential upside of 25.90%. Given United Therapeutics' higher probable upside, analysts clearly believe United Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dianthus Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Dianthus Therapeutics' net margin of -10,096.95%. United Therapeutics' return on equity of 20.18% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
United Therapeutics	41.56%	20.18%	17.98%

United Therapeutics has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,977.37	-$162.34M	-$4.15	N/A
United Therapeutics	$3.15B	6.98	$1.33B	$27.95	18.36

Summary

United Therapeutics beats Dianthus Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, Dianthus Therapeutics had 13 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Dianthus Therapeutics and 1 mentions for Genmab A/S. Dianthus Therapeutics' average media sentiment score of 1.01 beat Genmab A/S's score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Genmab A/S presently has a consensus target price of $39.50, indicating a potential upside of 18.09%. Dianthus Therapeutics has a consensus target price of $124.27, indicating a potential upside of 11.86%. Given Genmab A/S's higher possible upside, research analysts plainly believe Genmab A/S is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Genmab A/S has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.61	$963M	$1.27	26.34
Dianthus Therapeutics	$2.04M	2,977.37	-$162.34M	-$4.15	N/A

Genmab A/S has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Genmab A/S has a net margin of 19.08% compared to Dianthus Therapeutics' net margin of -10,096.95%. Genmab A/S's return on equity of 14.89% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Summary

Genmab A/S and Dianthus Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Dianthus Therapeutics (NASDAQ:DNTH) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

In the previous week, Dianthus Therapeutics had 8 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Dianthus Therapeutics and 6 mentions for BridgeBio Pharma. Dianthus Therapeutics' average media sentiment score of 1.01 beat BridgeBio Pharma's score of 0.29 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma has a net margin of -97.03% compared to Dianthus Therapeutics' net margin of -10,096.95%. BridgeBio Pharma's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Dianthus Therapeutics currently has a consensus target price of $124.27, indicating a potential upside of 11.86%. BridgeBio Pharma has a consensus target price of $100.79, indicating a potential upside of 23.67%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dianthus Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,977.37	-$162.34M	-$4.15	N/A
BridgeBio Pharma	$502.08M	31.73	-$724.93M	-$3.57	N/A

Dianthus Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Summary

BridgeBio Pharma beats Dianthus Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNTH vs. The Competition

Export

Metric	Dianthus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.07B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-26.77	11.62	272.60	24.24
Price / Sales	2,977.37	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	5.18	16.80	13.05	6.20
Net Income	-$162.34M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-4.19%	3.29%	2.09%	0.08%
1 Month Performance	6.02%	8.23%	6.64%	3.88%
1 Year Performance	357.20%	55.05%	25.02%	16.98%

Dianthus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNTH Dianthus Therapeutics	2.877 of 5 stars	$111.10 +1.5%	$124.27 +11.9%	+357.2%	$6.07B	$2.04M	N/A	80	News Coverage Positive News Insider Trade
MRNA Moderna	1.6484 of 5 stars	$60.57 +1.3%	$42.13 -30.4%	+434.9%	$23.88B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Options Volume
BNTX BioNTech	2.479 of 5 stars	$92.80 flat	$127.81 +37.7%	+5.1%	$23.47B	$3.25B	N/A	7,807	Trending News Options Volume
UTHR United Therapeutics	4.215 of 5 stars	$515.50 -2.7%	$646.00 +25.3%	+64.3%	$22.72B	$3.18B	18.44	1,400	News Coverage Positive News Insider Trade Options Volume
GMAB Genmab A/S	3.4694 of 5 stars	$30.85 -0.1%	$39.50 +28.0%	+35.7%	$19.25B	$3.72B	24.29	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNTH) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. MRNA, BNTX, UTHR, GMAB, and BBIO

How does Dianthus Therapeutics compare to Moderna?

Summary

How does Dianthus Therapeutics compare to BioNTech?

Summary

How does Dianthus Therapeutics compare to United Therapeutics?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. MRNA, BNTX, UTHR, GMAB, and BBIO

How does Dianthus Therapeutics compare to Moderna?

Do insiders and institutionals believe in DNTH or MRNA?

Is DNTH or MRNA more profitable?

Which has more risk and volatility, DNTH or MRNA?

Which has better earnings and valuation, DNTH or MRNA?

Does the media favor DNTH or MRNA?

Do analysts recommend DNTH or MRNA?

Summary

How does Dianthus Therapeutics compare to BioNTech?

Do analysts recommend DNTH or BNTX?

Do insiders & institutionals have more ownership in DNTH or BNTX?

Which has more volatility & risk, DNTH or BNTX?

Does the media prefer DNTH or BNTX?

Which has better valuation & earnings, DNTH or BNTX?

Is DNTH or BNTX more profitable?

Summary

How does Dianthus Therapeutics compare to United Therapeutics?

Does the media prefer DNTH or UTHR?

Do analysts recommend DNTH or UTHR?

Do insiders and institutionals have more ownership in DNTH or UTHR?

Which has more risk and volatility, DNTH or UTHR?

Is DNTH or UTHR more profitable?

Which has higher earnings and valuation, DNTH or UTHR?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Does the media refer more to GMAB or DNTH?

Do insiders and institutionals believe in GMAB or DNTH?

Do analysts recommend GMAB or DNTH?

Which has stronger valuation & earnings, GMAB or DNTH?

Which has more risk and volatility, GMAB or DNTH?

Is GMAB or DNTH more profitable?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Does the media favor DNTH or BBIO?

Is DNTH or BBIO more profitable?

Do analysts prefer DNTH or BBIO?

Do insiders and institutionals hold more shares of DNTH or BBIO?

Which has better valuation and earnings, DNTH or BBIO?

Which has more volatility & risk, DNTH or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools